DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Siplizumab
Siplizumab
Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
Targeted Therapies in B-Cell Non-Hodgkin Lymphomas
Psoriasis and the New Biologic Agents: Interrupting a T-AP Dance
Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell
Drug Treatments in Psoriasis
Modifications to the Harmonized Tariff Schedule of the United States To
I Regulations
Siplizumab, an Anti-CD2 Monoclonal Antibody, Induces a Unique Set of Immune Modulatory Effects Compared to Alemtuzumab and Rabbit Anti-Thymocyte Globulin in Vitro
Phase I Trial of Siplizumab in CD-2 Positive Lymphoproliferative Disease
(12) United States Patent (10) Patent No.: US 8,741,861 B2 Mann (45) Date of Patent: Jun
Population Pharmacokinetics of Siplizumab (MEDI-507) Implications for Dosing E
1 Abbreviated Title: Siplizumab/EPOCH-R in T/NK NHL NCI Protocol #: 09C0065 H Version Date: 11/21/2018 NCT Number: NCT01445535 P
INN Working Document 05.179 Update 2011
IUPAC Glossary of Terms Used in Immunotoxicology (IUPAC Recommendations 2012)*
Eee", Rpen. E. 632. A
(INN) for Biological and Biotechnological Substances
New Strategies in Peripheral T-Cell Lymphoma: Understanding Tumor Biology and Developing Novel Therapies
WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
Top View
WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
(12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
Novel Antibodies in the Treatment of Non-Hodgkin's Lymphoma
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Preventive Anti-Cd2 Treatment Does Not Impair Parasite Control in a Murine Toxoplasmosis Model
Treatment and Clinical Trials for PTCL
Wo 2010/095940 A2
Antibody-Drug Analogues
(12) United States Patent (10) Patent No.: US 8,716.450 B2 Ghayur Et Al
The Time to Target and Terminate the Threat of Ptcl
Wo 2012/149405 A2
Customs Tariff - Schedule Xxi - 1
International Nonproprietary Names for Pharmaceutical Substances (INN)
Study Protocol
Efficacy and Safety of Biologics in the Treatment of Moderate to Severe Psoriasis: a Comprehensive Meta-Analysis of Randomized Controlled Trials
Activated B-Cell
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Immunomodulatory Treatment for the Intractable Paediatric Epilepsies Luis E
Systemic T-Cell Lymphoma: Diagnosis and Treatment (First Line and Relapse Disease)
(INN) for Biological and Biotechnological Substances
Thalidomide - Wikipedia, the Free Encyclopedia
Assessment of the Evolution of Cancer Treatment Therapies
Classical to Current Approach for Treatment of Psoriasis: a Review
EBV-Related Lymphoproliferative Disease Complicatingtherapy With